drugset / Trial / NCT02646774

Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis

NCT02646774

Phase 4 Terminated 43 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of intravenous micafungin for the treatment of proven or probable fungal infections caused by Aspergillus sp. (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.

Timeline

Start
2014-03-01
Primary completion
2015-06-26
Completion
2015-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide Intravenous